Allison Betof Warner, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the future of cancer treatment in regards to cellular therapies and cancer vaccines. Tumor infiltrating lymphocytes (TILs) are showing promise in solid tumors including melanoma, head and neck cancer, cervical cancer and lung cancer. Efficacy has been observed with T-cell receptor (TCR) therapy, although not particularly in melanoma. The impact of vaccines on the future of cancer treatment remains uncertain, although early efficacy signals have been observed with personalized mRNA vaccines. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.

свернуть